Tempo Therapeutics discloses $14 million raised in debt offering

Tempo Therapeutics, Inc. filed a Form D notice with the Securities and Exchange Commission dated September 11, 2026, disclosing an exempt securities offering. The filing marks a new notice, with a date of first sale listed as August 27, 2026.¹

The offering is structured as debt.¹ The company set a total offering amount of $14,500,000, with $14,000,000 already sold and $500,000 remaining to be sold.¹ The filing states 43 investors have already put money into the offering.¹

Tempo claimed the Rule 506(b) exemption under Regulation D.¹ The minimum investment accepted from any outside investor was listed as $0.¹ The company said it does not intend the offering to last more than one year.¹

The filing reported $0 in sales commissions and $0 in finders' fees, both listed as estimates.¹ Use of proceeds toward payments to executive officers, directors, or promoters was also listed as $0, an estimate.¹

Tempo Therapeutics is based at 3030 Bunker Hill Street, Suite 308, in San Diego, California.¹ The company classified its industry as biotechnology within the health care sector.¹ Related persons named in the filing include Executive Officer and Director Westbrook Weaver, and Directors Donald Griffin, Biren Mehta, Steven Sands, and Eric Richman, who also serves as Executive Officer.¹

The notice was signed by Eric Richman as Chief Executive Officer, dated September 11, 2026.¹